NEW YORK (GenomeWeb) – Some of the same precision medicine capabilities coming into focus for full-blown cancers are starting to glint on the horizon for individuals with pre-cancerous conditions and their clinicians.
"You hear about precision medicine in the context of [cancer] treatment. But you don't hear about precision medicine in the context of early-stage disease," explained Sudhir Srivastava, chief of the National Cancer Institute (NCI) cancer prevention division's cancer biomarkers research group.